Education
About Us
Working with TipRanks
Follow Us
Dawnrays Pharmaceutical Holdings Ltd. (HK:2348)
:2348
RESEARCH TOOLSreports
Total Valuation
Dawnrays Pharmaceutical Holdings Ltd. has a market cap or net worth of HK$1.85B. The enterprise value is ―.
Market CapHK$1.85B
Enterprise Value―
Share Statistics
Dawnrays Pharmaceutical Holdings Ltd. has 1,502,885,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,502,885,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dawnrays Pharmaceutical Holdings Ltd.’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 9.33%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)9.33%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee896.29K
Profits Per Employee538.42K
Employee Count1,183
Asset Turnover0.26
Inventory Turnover1.57
Valuation Ratios
The current PE Ratio of Dawnrays Pharmaceutical Holdings Ltd. is 3.05. Dawnrays Pharmaceutical Holdings Ltd.’s PEG ratio is ―.
PE Ratio3.05
PS Ratio0.00
PB Ratio0.49
Price to Fair Value0.52
Price to FCF38.40
Price to Operating Cash Flow9.50
PEG Ratio―
Income Statement
In the last 12 months, Dawnrays Pharmaceutical Holdings Ltd. had revenue of 1.06B and earned 564.94M in profits. Earnings per share was 0.38.
Revenue1.06B
Gross Profit577.63M
Operating Income367.91M
Pretax Income636.95M
Net Income564.94M
EBITDA280.49M
Earnings Per Share (EPS)0.38
Cash Flow
In the last 12 months, operating cash flow was 171.45M and capital expenditures -129.25M, giving a free cash flow of 42.20M billion.
Operating Cash Flow171.45M
Free Cash Flow42.20M
Free Cash Flow per Share0.03
Dividends & Yields
Dawnrays Pharmaceutical Holdings Ltd. pays an annual dividend of HK$0.094, resulting in a dividend yield of 5.12%
Dividend Per ShareHK$0.094
Dividend Yield5.12%
Payout Ratio11.76%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change12.84%
50-Day Moving Average1.11
200-Day Moving Average1.11
Relative Strength Index (RSI)79.54
Average Volume (3m)252.47K
Important Dates
Dawnrays Pharmaceutical Holdings Ltd. upcoming earnings date is Aug 22, 2025, TBA Not Confirmed.
Last Earnings DateMar 28, 2025
Next Earnings DateAug 22, 2025
Ex-Dividend DateMay 27, 2025
Financial Position
Dawnrays Pharmaceutical Holdings Ltd. as a current ratio of 3.97, with Debt / Equity ratio of 1.04%
Current Ratio3.97
Quick Ratio3.42
Debt to Market Cap0.02
Net Debt to EBITDA-4.01
Interest Coverage Ratio101.97
Taxes
In the past 12 months, Dawnrays Pharmaceutical Holdings Ltd. has paid 74.19M in taxes.
Income Tax74.19M
Effective Tax Rate0.12
Enterprise Valuation
Dawnrays Pharmaceutical Holdings Ltd. EV to EBITDA ratio is 2.15, with an EV/FCF ratio of 13.50.
EV to Sales0.57
EV to EBITDA2.15
EV to Free Cash Flow13.50
EV to Operating Cash Flow2.73
Balance Sheet
Dawnrays Pharmaceutical Holdings Ltd. has HK$1.37B in cash and marketable securities with ¥34.72M in debt, giving a net cash position of -HK$1.33B billion.
Cash & Marketable SecuritiesHK$1.37B
Total Debt¥34.72M
Net Cash-HK$1.33B
Net Cash Per Share-HK$0.89
Tangible Book Value Per ShareHK$1.85
Margins
Gross margin is 50.18%, with operating margin of 34.70%, and net profit margin of 53.28%.
Gross Margin50.18%
Operating Margin34.70%
Pretax Margin60.07%
Net Profit Margin53.28%
EBITDA Margin26.45%
EBIT Margin19.06%
Analyst Forecast
The average price target for Dawnrays Pharmaceutical Holdings Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-9.95%
EPS Growth Forecast67.56%